The current study’s focus solely on semaglutide, among various GLP-1 receptor agonists, and specifically on thyroid cancer, is guided by the imperative to elucidate the nuanced risk profiles attributed to different therapeutic agents within the same class. The gene discussed is GLP1R; the disease is thyroid gland carcinoma.